Chinese Clinical Trial Registry (Hong Kong), Hong Kong Chinese Medicine Clinical Study Centre, The EQUATOR China Centre, School of Chinese Medicine, Hong Kong Baptist University (HKBU), Room 307, Jockey Club School of Chinese Medicine Building, 7 Baptist University Road, Kowloon Tong, Kowloon, HKSAR, China.
Department of Computer Science, HKBU Faculty of Science, Hong Kong Baptist University, Hong Kong, SAR, China.
BMC Med Res Methodol. 2020 Jul 17;20(1):192. doi: 10.1186/s12874-020-01077-w.
Although the WHO Trial Registration Data Set (TRDS) has been published for many years, the quality of clinical trial registrations with traditional Chinese medicine (TCM) is still not satisfactory, especially about the inadequate reporting on TCM interventions. The development of the WHO TRDS for TCM Extension 2020 (WHO TRDS-TCM 2020) aims to address this inadequacy.
A group of clinical experts, methodologists, epidemiologists, and editors has developed this WHO TRDS-TCM 2020 through a comprehensive process, including the baseline survey, draft of the initial items, three-round of Delphi survey, solicitation of comments, revision, and finalization.
The WHO TRDS-TCM 2020 statement extends the latest version (V.1.3.1) of TRDS published in November 2017. The checklist includes 11 extended items (including subitems), namely Source(s) of Monetary or Material Support (Item 4), Scientific Title (Item 10a and 10b), Countries of Recruitment (Item 11), Health Condition(s) or Problem(s) Studied (Item 12), Intervention(s) (Item 13a, 13b and 13c), Key Inclusion and Exclusion Criteria (Item 14), Primary and Key Secondary Outcomes (Item 19 to 20), and Lay Summary (Item B1). For Item 13 (Interventions), three common TCM interventions--i.e., Chinese herbal medicine formulas, acupuncture and moxibustion-are elaborated.
The group hopes that the WHO TRDS-TCM 2020 can improve the reporting quality and transparency of TCM trial registrations, assist registries in assessing the registration quality of TCM trials, and help readers understand TCM trial design.
世界卫生组织(WHO)试验注册数据集(TRDS)已经发布多年,但中药临床试验的注册质量仍不尽如人意,尤其是关于中药干预措施的报告不充分。制定 2020 年版 WHO 中药扩展 TRDS(WHO TRDS-TCM 2020)的目的是解决这一不足。
一组临床专家、方法学家、流行病学家和编辑通过一个全面的过程制定了这个 WHO TRDS-TCM 2020,包括基线调查、初始项目草案、三轮德尔菲调查、征求意见、修订和定稿。
WHO TRDS-TCM 2020 声明扩展了 2017 年 11 月发布的最新版 TRDS(V.1.3.1)。清单包括 11 个扩展项目(包括子项),即货币或物质支持的来源(项目 4)、科学标题(项目 10a 和 10b)、招募国家(项目 11)、研究的健康状况或问题(项目 12)、干预措施(项目 13a、13b 和 13c)、主要和关键次要结局(项目 19 至 20)和通俗摘要(项目 B1)。对于项目 13(干预措施),详细阐述了三种常见的中药干预措施,即中药方剂、针灸和艾灸。
该小组希望 WHO TRDS-TCM 2020 能够提高中药试验注册报告的质量和透明度,帮助注册机构评估中药试验的注册质量,并帮助读者了解中药试验设计。